Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Stock Rated “Moderate Buy” by Sell-Side Brokerages

Shares of Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) have earned a consensus rating of “Moderate Buy” from the eight ratings firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1-year price target among brokers that have covered the stock in the last year is $52.83.

A number of research firms recently commented on PTHS. Oppenheimer dropped their price target on shares of Pelthos Therapeutics from $66.00 to $64.00 and set an “outperform” rating for the company in a research note on Friday, August 14th. Alliance Global Partners reissued a “buy” rating on shares of Pelthos Therapeutics in a research report on Monday, October 26th. Zacks Research raised shares of Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, November 4th. Finally, Lake Street Capital decreased their price objective on shares of Pelthos Therapeutics from $50.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, October 12th.

Institutional Investors Weigh In On Pelthos Therapeutics

An institutional investor recently raised its stake in Pelthos Therapeutics stock. Pale Fire Capital SE raised its holdings in shares of Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) by 59.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,919 shares of the company’s stock after purchasing an additional 4,819 shares during the quarter. Pale Fire Capital SE owned 0.38% of Pelthos Therapeutics worth $271,000 at the end of the most recent reporting period. 77.96% of the stock is currently owned by institutional investors.

Pelthos Therapeutics Stock Up 5.5%

NYSEAMERICAN PTHS opened at $9.39 on Thursday. The company has a quick ratio of 1.31, a current ratio of 1.98 and a debt-to-equity ratio of 3.40. Pelthos Therapeutics has a 52 week low of $8.72 and a 52 week high of $37.40. The firm has a market capitalization of $35.96 million, a price-to-earnings ratio of -0.43 and a beta of 3.41. The company has a fifty day moving average of $18.84 and a two-hundred day moving average of $23.62.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last announced its earnings results on Thursday, August 13th. The company reported ($6.62) earnings per share for the quarter. The firm had revenue of $15.60 million during the quarter. Pelthos Therapeutics had a negative net margin of 165.24% and a negative return on equity of 204.71%. On average, analysts predict that Pelthos Therapeutics will post -15.22 earnings per share for the current year.

About Pelthos Therapeutics

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).